Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Eurostars Project E!10859 DOAC-STOP: A novel inhibitor to prevent uncontrolled bleedings in anticoagulant users

Reference number
Coordinator Adlego Biomedical AB
Funding from Vinnova SEK 0
Project duration April 2017 - March 2019
Status Completed
Venture Eurostars

Purpose and goal

DOAC-STOP aims to develop PseudoXa, a biological for the instantaneous restoration of blood clotting activity in patients with major bleedings as a result of blood thinners.

Expected results and effects

PseudoXa will be produced and the preclinical efficacy, pharmacokinetics (PK), and toxicity (TOX) of PseudoXa will be determined in vitro and in vivo. The end result will be a completed preclinical study dossier for PseudoXa. After the project, clinical phase development will be initiated.

Planned approach and implementation

WP2: Focuses on developing research models, identifying read-out parameters, and setting up analytical techniques for efficacy, PK, and toxicity studies on biologicals that act on the coagulation cascade. WP4: The PK and PD properties of PseudoXa will be assessed to evaluate the biological and physiological characteristics of PseudoXa. WP5: Repeated dose toxicity studies will ´cover´ for the intended duration of the clinical studies. Furthermore, the duration of the toxicology study will be in line with mostly used duration of toxicology studies.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2017-01618

Page statistics